The main breakthrough in tumor immunotherapy was the discovery of immune checkpoint
(IC) proteins, which act as a potent suppressor of the immune system by a myriad of …

Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …

We performed proteogenomic characterization of intrahepatic cholangiocarcinoma (iCCA)
using paired tumor and adjacent liver tissues from 262 patients. Integrated proteogenomic …

Lung adenocarcinoma (LUAD) is the most frequent subtype of lung cancer worldwide.
However, the survival rate of LUAD patients remains low. N6-methyladenosine (m 6 A) and …

The number of druggable tumor-specific molecular aberrations has grown substantially in
the past decade, with a significant survival benefit obtained from biomarker matching …

Background Tumor mutational burden (TMB) measurements aid in identifying patients who
are likely to benefit from immunotherapy; however, there is empirical variability across panel …

Abstract Characterization of tumors utilizing next‐generation sequencing methods, including
assessment of the number of somatic mutations (tumor mutational burden [TMB]), is currently …

Background Furmonertinib (AST2818) is a third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI) targeting both sensitising EGFR and EGFR Thr790Met …

Background Despite tremendous advances in cancer research, breast cancer (BC) remains
a major health concern and is the most common cancer affecting women worldwide. Breast …

Purpose: Our preclinical work suggests that appropriate angiogenesis inhibition could
potentiate PD-1/PD-L1 blockade via alleviating hypoxia, increasing infiltration of CD8+ T …